Grunenthal GmbH
Pascalstraße 6
Aachen
52076
Germany
Tel: 0241-569-1111
Fax: 0241-569-1112
Website: http://www.gruenenthal.de/
Email: Service@grunenthal.de
55 articles about Grunenthal GmbH
-
Grünenthal and NovaQuest Enter Agreement to Advance the Resiniferatoxin Global Phase III Program in Osteoarthritis
3/29/2022
Grünenthal and NovaQuest announced that they have entered an agreement to advance the global clinical Phase III programme of Grünenthal's asset resiniferatoxin.
-
Grünenthal Expands Its Network Through Innovation Hub in Boston
1/29/2020
Grünenthal announced that it has officially inaugurated its Innovation Hub in Boston, Massachusetts to strengthen and expand its network with leading scientists and institutions.
-
Two weeks after acquiring two drugs from AstraZeneca in a $700 million deal, Germany-based Grünenthal flexed its M&A muscle again to acquire Averitas Pharma to extend its commercial footprint in the United States.
-
AstraZeneca Continues to Divest Products, Sells Rights to RSV Drug to Sobi for $1.5 Billion
11/14/2018
Two weeks after reporting a 45 percent growth in revenue for the third quarter, compared to last year, Swedish Orphan Biovitrum AB (Sobi) has snapped up the U.S. rights to AstraZeneca’s respiratory drug, Synagis, a drug used to treat RSV in infants, for $1.5 billion. -
Privately-held Grunenthal GmbH will pay AstraZeneca $700 million for the prescription medicine rights to acid-reflux medicine Nexium. The deal with AstraZeneca represents the largest investment in Grünenthal company history.
-
Sanofi announced that Elias Zerhouni, head of Global Research and Development, is retiring on June 30. The company has appointed John Reed to replace him as of July 1.
-
Grunenthal Opens Innovation Hub In Boston As Next Step In Strategy To Drive External Innovation In Pain, Specialty Therapeutics And Medical Devices Forward
5/10/2017
-
Mark Fladrich Appointed New Chief Commercial Officer (CCO) At Grunenthal
5/9/2017
-
23andMe And German Pain Specialist Grunenthal Explore The Genetics Of Pain To Help Identify New Treatments For Patients
5/3/2017
-
New Grunenthal CEO Forges Ahead with Treatment for Complex Regional Pain Syndrome
1/18/2017
-
Grunenthal Release: Company Introduces Latin America’s Most Modern Women’s Health Products Plant
1/16/2017
-
Grunenthal Receives Breakthrough Therapy Designation From U.S. FDA For Neridronic Acid For The Treatment Of CRPS
12/16/2016
-
Grunenthal To Acquire Commercialization Rights Of Qutenza In Europe From Astellas Pharma Europe
12/12/2016
-
Grunenthal Has Acquired US-Based Thar Pharma To Expand Its Development Portfolio Of Treatment Options For CRPS (Complex Regional Pain Syndrome), A Serious, Disabling Orphan Disease
11/17/2016
-
Gabriel Baertschi Takes Office As New CEO Of Grunenthal As Of October 1, 2016
10/4/2016
-
A Research Consortium Under The Direction Of Grunenthal Will Receive A Grant Of €1.5 Million From The European Fund For Regional Development And The Federal State Of North Rhein-Westphalia
9/27/2016
-
Grunenthal Appoints Gabriel Baertschi As Chairman Of The Corporate Executive Board And Chief Executive Officer Effective October 1, 2016
6/7/2016
-
AstraZeneca PLC Unloads Gout Drug Rights to Grunenthal in $230 Million+ Deal
6/2/2016
-
Grunenthal Announces Exclusive License Agreement For Commercialization Of Innovative Surgical Glue In The EU And Latin America
5/12/2016
-
Grunenthal To Acquire Almirall de Mexico, S.A. de C.V.
3/16/2016